PT2767291T - Tratamento de doenças de armazenanto de glicogénio tipo ii - Google Patents

Tratamento de doenças de armazenanto de glicogénio tipo ii

Info

Publication number
PT2767291T
PT2767291T PT141678821T PT14167882T PT2767291T PT 2767291 T PT2767291 T PT 2767291T PT 141678821 T PT141678821 T PT 141678821T PT 14167882 T PT14167882 T PT 14167882T PT 2767291 T PT2767291 T PT 2767291T
Authority
PT
Portugal
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
PT141678821T
Other languages
English (en)
Portuguese (pt)
Inventor
Chen Yuan-Tsong
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2767291(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of PT2767291T publication Critical patent/PT2767291T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT141678821T 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii PT2767291T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18

Publications (1)

Publication Number Publication Date
PT2767291T true PT2767291T (pt) 2016-10-25

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
PT141678821T PT2767291T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT16178390T PT3108895T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT70010913T PT1782825E (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT16178390T PT3108895T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT70010913T PT1782825E (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii

Country Status (17)

Country Link
US (10) US7056712B2 (enExample)
EP (4) EP3449934B1 (enExample)
JP (10) JP5113312B2 (enExample)
AT (1) ATE355075T1 (enExample)
AU (3) AU7194101A (enExample)
BR (1) BR0113006A (enExample)
CA (1) CA2416492C (enExample)
CY (2) CY1120977T1 (enExample)
DE (1) DE60126947T2 (enExample)
DK (5) DK2767291T3 (enExample)
ES (5) ES2523024T3 (enExample)
LT (3) LT3449934T (enExample)
MX (1) MXPA03000474A (enExample)
PT (5) PT2767291T (enExample)
SI (3) SI3449934T1 (enExample)
TW (1) TWI280882B (enExample)
WO (1) WO2002005841A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523024T3 (es) * 2000-07-18 2014-11-20 Duke University Tratamiento de glucogenosis de tipo II
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
WO2004064750A2 (en) * 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010005565A2 (en) 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
KR20250004926A (ko) 2014-09-30 2025-01-08 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
JP6821192B2 (ja) * 2015-05-07 2021-01-27 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
HK1258073A1 (zh) * 2015-08-31 2019-11-01 Duke University 治疗细胞质糖原贮积失调的方法和组合物
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102790256B1 (ko) 2016-03-30 2025-04-04 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
WO2017173060A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL305449B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
DK3624831T5 (da) 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
SG11202002457RA (en) 2017-09-22 2020-04-29 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
AU3113700A (en) 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ES2523024T3 (es) * 2000-07-18 2014-11-20 Duke University Tratamiento de glucogenosis de tipo II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
ES2277931T3 (es) 2007-08-01
SI3108895T1 (sl) 2019-01-31
US20160184410A1 (en) 2016-06-30
HK1103363A1 (en) 2007-12-21
US20180185457A1 (en) 2018-07-05
ES2799882T3 (es) 2020-12-22
EP1301201A1 (en) 2003-04-16
US20150004152A1 (en) 2015-01-01
US8900552B2 (en) 2014-12-02
US20080175833A1 (en) 2008-07-24
US20020110551A1 (en) 2002-08-15
MXPA03000474A (es) 2003-10-06
US7056712B2 (en) 2006-06-06
DK1782825T3 (da) 2014-11-03
JP2017137357A (ja) 2017-08-10
PT3449934T (pt) 2020-06-25
EP3108895A1 (en) 2016-12-28
DE60126947D1 (de) 2007-04-12
US20210169996A1 (en) 2021-06-10
DK3108895T3 (en) 2018-11-26
US20050123531A1 (en) 2005-06-09
JP2016056206A (ja) 2016-04-21
ATE355075T1 (de) 2006-03-15
PT1301201E (pt) 2007-03-30
CA2416492A1 (en) 2002-01-24
DK2767291T3 (en) 2016-12-05
BR0113006A (pt) 2004-10-19
SI2767291T1 (sl) 2016-11-30
ES2700865T3 (es) 2019-02-19
US9907839B2 (en) 2018-03-06
CA2416492C (en) 2008-04-29
US20100254966A1 (en) 2010-10-07
EP3449934A1 (en) 2019-03-06
PT1782825E (pt) 2014-11-04
EP3108895B1 (en) 2018-09-19
EP2767291A2 (en) 2014-08-20
DK3449934T3 (da) 2020-06-29
WO2002005841A1 (en) 2002-01-24
ES2523024T3 (es) 2014-11-20
EP2767291A3 (en) 2014-10-08
TWI280882B (en) 2007-05-11
JP5113312B2 (ja) 2013-01-09
LT3108895T (lt) 2018-11-26
JP2013231081A (ja) 2013-11-14
EP1301201B1 (en) 2007-02-28
LT3449934T (lt) 2020-08-10
PT3108895T (pt) 2018-12-18
US20120058132A1 (en) 2012-03-08
JP2018002749A (ja) 2018-01-11
AU7194101A (en) 2002-01-30
AU2010200487A1 (en) 2010-03-04
AU2001271941B2 (en) 2007-03-01
CY1120977T1 (el) 2019-12-11
HK1197656A1 (en) 2015-02-06
JP2008081507A (ja) 2008-04-10
JP2012006953A (ja) 2012-01-12
LT2767291T (lt) 2016-11-25
ES2599401T3 (es) 2017-02-01
EP2767291B1 (en) 2016-09-14
JP2014185187A (ja) 2014-10-02
US20130195834A1 (en) 2013-08-01
US9370556B2 (en) 2016-06-21
CY1123084T1 (el) 2021-10-29
JP5792774B2 (ja) 2015-10-14
US10792341B2 (en) 2020-10-06
JP2020019822A (ja) 2020-02-06
EP3449934B1 (en) 2020-05-20
SI3449934T1 (sl) 2020-09-30
HK1054690A1 (en) 2003-12-12
JP2004503598A (ja) 2004-02-05
JP2018199721A (ja) 2018-12-20
DE60126947T2 (de) 2007-10-31
DK1301201T3 (da) 2007-04-02
JP6163216B2 (ja) 2017-07-12

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2005089426A3 (en) Method of treating sepsis
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2002051404A8 (fr) Compositions orales
EP1782825A3 (en) Treatment of glycogen storage diseases type II
UA29106A (uk) Спосіб лікування вібраційної хвороби
UA31369A (uk) Спосіб покращання кровотоку пілородуоденальної зони